BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 37934376)

  • 1. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States.
    Yee CW; Harvey MJ; Xin Y; Kirson NY
    Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia.
    Song R; Jeet V; Sharma R; Hoyle M; Parkinson B
    Pharmacoeconomics; 2022 Aug; 40(8):807-821. PubMed ID: 35761117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review.
    Arafa AT; Jain A; Skrobanek P; Humphrey B; Froelich JW; Antonarakis ES
    Prostate; 2023 Jun; 83(9):863-870. PubMed ID: 36999911
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
    Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
    Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
    JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
    de Feria Cardet RE; Hofman MS; Segard T; Yim J; Williams S; Francis RJ; Frydenberg M; Lawrentschuk N; Murphy DG; De Abreu Lourenco R
    Eur Urol; 2021 Mar; 79(3):413-418. PubMed ID: 33341285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piflufolastat F-18 (
    Voter AF; Werner RA; Pienta KJ; Gorin MA; Pomper MG; Solnes LB; Rowe SP
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):681-694. PubMed ID: 35603510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory cost-effectiveness analysis of
    Gordon LG; Elliott TM; Joshi A; Williams ED; Vela I
    Clin Exp Metastasis; 2020 Apr; 37(2):305-312. PubMed ID: 32064552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing digital to analog prostate-specific membrane antigen-targeted piflufolastat 18 F PET/CT in prostate cancer patients in early biochemical failure.
    Maliha PG; Nolet B; Ebrahim A; Abikhzer G; Chaussé G; Bahoric B; Niazi T; Probst S
    Nucl Med Commun; 2023 Mar; 44(3):187-193. PubMed ID: 36525002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of
    Galgano SJ; McDonald AM; Rais-Bahrami S; Porter KK; Choudhary G; Burgan C; Bhambhvani P; Nix JW; Morgan DE; Li Y; Thomas JV; McConathy J
    AJR Am J Roentgenol; 2021 Sep; 217(3):720-729. PubMed ID: 33052718
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of hormonal therapy on
    Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
    Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Calais J; Fendler WP; Herrmann K; Eiber M; Ceci F
    J Nucl Med; 2018 May; 59(5):789-794. PubMed ID: 29242404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSMA-targeted Radiotracers versus
    Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
    Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Comparison of
    Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
    Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Mehrens D; Kramer KKM; Unterrainer LM; Beyer L; Bartenstein P; Froelich MF; Tollens F; Ricke J; Rübenthaler J; Schmidt-Hegemann NS; Herlemann A; Unterrainer M; Kunz WG
    J Natl Compr Canc Netw; 2023 Jan; 21(1):43-50.e2. PubMed ID: 36634610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
    Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
    Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
    Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
    Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.